Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-1805
- Development stage
- Preclinical
- Lead developer
- ImmunoForge
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
PF-1805 is a recombinant polypeptide drug candidate developed by Immunoforge. It acts as a modulator of NPRL2 (NPR2-like, GATOR1 complex subunit) and targets the natriuretic peptide receptor B (NPR-B). The drug is being investigated primarily for the treatment of achondroplasia, a congenital disorder characterized by abnormal bone growth. Its mechanism involves modulation of NPRL2/NPR-B signaling pathways, which are implicated in skeletal development. PF-1805 utilizes Immunoforge's half-life extension platform technology to enable weekly dosing and potentially improve therapeutic outcomes in patients with achondroplasia[1][3].
02
Targets
NPRL2 (Nitrogen permease regulator 2-like protein)NPR2 (C-type Natriuretic Peptide Receptor B)
Beyond the preview
Go deeper on PF-1805.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-1805.